Research On Pharmacokinetics Of Levosimendan

Heart insufficiency is a chronic disease with many causes and symptoms. It has a complex patho-process and physio-process.In this circumstance the heart function was hurt by various kinds of patho-factors, and it leads to insufficient cardiac output and insufficient oxygen supply to whole body,which is characteristic as a clinic symptom with the key feature of insufficient tissue hemoperfusion and congestion in general circulation or pulmonary circulation. With the increasing of cardiovascular system disease and the tendency of population ageing,the incidence of heart insufficiency is increasing and the rates of mutilation and fatality are both higher than before.So it is one of the most important topics to delay the advancement of the heart insufficiency,to decrease the death rate of patients and to improve the life qualitity of the patients.The basic principle of drug treatment for heart insufficiency is cardia stimulation, diuresis and blood vessel expansion. The drugs with positive inotropic effect are always used to clinical therapy,inclusing cardiotonic glycoside groups, diuretic agent, P-receptor blocking pharmacon, part excitomotory, blood vessel expender and angiotensin I converting enzyme inhibitor (ACEI). In recent years,the research and development of calcium sensitizers has become a popular topic.They will afford a new way for the therapy on heart insufficiency.Levosimendan, photic isomeride of Simendan,is a new type of calcium sensitizer.It can strengthen sensitivity to Ca²⁺ by binding to troponin C in cardiac muscle,then generates positive inotropic effect and reinforce myocardial contractile force without increasing Ca²⁺ concentration. The effect is Ca²⁺ concentration-dependent and available at high Ca²⁺ concentration only.Levosimendan has no harm...